Oesophageal Cancer

Overview

Oesophageal cancer arises from the epithelial lining of the oesophagus and is one of the deadliest solid-organ malignancies. It is the 8th most common cancer worldwide and the 6th leading cause of cancer death, with an annual mortality that closely mirrors its incidence because most patients present with locally advanced or metastatic disease. Two principal histological types — squamous cell carcinoma (SCC) and adenocarcinoma (ADC) — have distinct epidemiology, biology, anatomical distribution, risk factors and, increasingly, distinct therapeutic strategies. Examiners repeatedly test the contrast between these two subtypes, the multimodal treatment paradigm, the surgical anatomy of the oesophagus, and the staging of gastro-oesophageal junction (GOJ) tumours. [1]

[1]

Surgical Anatomy of the Oesophagus

A confident command of oesophageal anatomy is the foundation for understanding tumour spread, surgical approaches, lymphadenectomy fields, and the complications of oesophagectomy. Examiners expect a precise, segmented description. [1]

Anatomical Course and Length

The oesophagus is a muscular tube approximately 25 cm long (range 23–28 cm) beginning at the cricopharyngeus (upper oesophageal sphincter) at the level of C6 (15 cm from the incisors) and ending at the cardia of the stomach (lower oesophageal sphincter) at the level of T10–T11 (40 cm from the incisors). It has three normal narrowings where foreign bodies, caustic strictures and tumours preferentially lodge: the cricopharyngeus (15 cm), the aortic and left main bronchus crossover (25 cm), and the diaphragmatic hiatus (40 cm). [1]

Three Anatomical Segments

For staging and surgical planning the oesophagus is divided into three segments (AJCC 8th edition): [1]

• Cervical oesophagus — from the cricopharyngeus (C6) to the thoracic inlet (at the suprasternal notch), roughly 15–18 cm from the incisors. Lymphatic drainage is to cervical and supraclavicular nodes; tumours here are often treated with definitive chemoradiotherapy (the larynx and pharynx are the surgical boundaries).
• Intrathoracic (thoracic) oesophagus — the longest segment, further subdivided into upper thoracic (18–24 cm), mid thoracic (24–32 cm) and lower thoracic (32–40 cm). Lymphatic drainage is to mediastinal nodes (paratracheal, subcarinal, para-oesophageal) and then to coeliac nodes inferiorly. This is the segment where lymphatic spread is bidirectional — cranially and caudally — which is the rationale for extended (3-field) lymphadenectomy in some centres.
• Abdominal oesophagus / gastro-oesophageal junction — from the diaphragmatic hiatus to the gastric cardia, roughly 1–2 cm long. Drainage is to left gastric and coeliac nodes. Adenocarcinomas arising here are classified by the Siewert system. [1]

Blood Supply

The blood supply is segmental, which has direct implications for surgical anastomotic healing (a relative watershed exists in the mid-thoracic segment). [1]

• Cervical oesophagus — inferior thyroid artery (branch of the subclavian via thyrocervical trunk); venous drainage via the inferior thyroid veins.
• Thoracic oesophagus — bronchial arteries (direct branches of the descending aorta, usually two on the left and one on the right) and direct oesophageal branches from the descending thoracic aorta; venous drainage via the azygos, hemiazygos and accessory hemiazygos veins.
• Abdominal oesophagus and GOJ — left gastric artery (from the coeliac trunk) and the left inferior phrenic artery; venous drainage via the left gastric (coronary) vein into the portal vein. [1]

Clinical pearl: The lower oesophagus is a classical portosystemic anastomosis — the union of the azygos (systemic) and left gastric (portal) venous systems. Portal hypertension shunts blood into this anastomosis, producing oesophageal (and GOJ) varices, the rupture of which is a surgical and endoscopic emergency entirely distinct from cancer but anatomically overlapping. [1]

Lymphatic Drainage

Lymphatics run in the submucosa for long distances before emerging, which is why skip metastases and wide nodal spread are characteristic of oesophageal cancer. Three lymphatic territories: [1]

1. Upper third → deep cervical, supraclavicular, paratracheal nodes.
2. Middle third → paratracheal, subcarinal, para-oesophageal mediastinal nodes; bidirectional spread to both cervical and coeliac basins.
3. Lower third / GOJ → left gastric, coeliac, lesser curve and hepatoduodenal nodes. [1]

The absence of a serosa in most of the thoracic oesophagus (only an adventitia) allows early transmural spread into adjacent vital structures — the aorta, trachea, left main bronchus, pericardium, left atrium, and vertebral column — which determines resectability (T4a vs T4b). [1]

Nerve Supply and Surgical Significance

• Motor — the oesophagus has an extrinsic parasympathetic supply (vagus) and an intrinsic enteric nervous system (Auerbach's myenteric plexus between the longitudinal and circular muscle, Meissner's submucosal plexus). The upper third is skeletal (striated) muscle (vagus via the recurrent laryngeal and pharyngeal branches); the lower two-thirds is smooth muscle.
• The recurrent laryngeal nerve (RLN) ascends in the tracheo-oesophageal groove and is at risk during cervical and upper thoracic dissection — injury causes hoarseness and aspiration, a common post-operative complication and a sign of locally advanced tumour at presentation.
• Sympathetic chains lie posteriorly; invasion causes Horner's syndrome (ptosis, miosis, anhidrosis) — a red-flag sign of T4b disease. [1]

Histological Layers

From within outward: mucosa (non-keratinising stratified squamous epithelium normally, becoming simple columnar with goblet cells in Barrett's metaplasia) → lamina propria → muscularis mucosae (a critical landmark: invasion through it defines T1a vs T1b and the threshold for lymphatic spread) → submucosa → muscularis propria (inner circular, outer longitudinal) → adventitia (no serosa). The depth of invasion through these layers is precisely what the T stage measures. [1]

Epidemiology

Oesophageal cancer accounts for roughly 600,000 new cases and over 500,000 deaths per year worldwide. The incidence is strikingly geographically heterogeneous — a 20-fold variation between high- and low-risk regions — and the two histologies show opposite time-trends. [1]

Squamous cell carcinoma (SCC) is the most common histology worldwide (around 85% of global cases), concentrated in the "oesophageal cancer belt" stretching from northern Iran across Central Asia to northern China, and in parts of East and South Africa. In these regions incidence can exceed 100 per 100,000. SCC arises predominantly in the upper and middle thirds. Globally its incidence is slowly falling. [1]

Adenocarcinoma (ADC) is now the dominant histology in North America, Western Europe, the UK and Australia, and has been the fastest-increasing cancer in Western men over the past four decades, driven by the epidemics of obesity, GORD and Barrett's oesophagus. ADC arises in the lower third and GOJ. It affects white males disproportionately (male-to-female ratio 6:1 in some series). [1]

Prognosis remains poor overall because symptoms develop late: 5-year survival across all stages is roughly 20%, though this rises dramatically with early (mucosal) disease and falls under 5% once distant metastases are present. [1]

Risk Factors

[1]

Synergism: Alcohol and tobacco together confer a risk far greater than the sum of their individual risks for SCC — a high-yield examination point. Tylosis (Howel-Evans syndrome) is a rare autosomal-dominant condition with palmoplantar keratoderma and an oesophageal SCC lifetime risk approaching 100%, linked to a mutation near the RHBDF2 gene on chromosome 17q25. It is the single highest-cancer-risk hereditary syndrome an MBBS student should know. [1]

Pathology and Pathogenesis

Squamous Cell Carcinoma — Pathway

SCC arises from the stratified squamous epithelium through a multistep sequence: basal cell hyperplasia → epithelial dysplasia (mild, moderate, severe) → carcinoma in situ → invasive carcinoma. The tumour may grow as a polypoid/fungating mass, an ulcerative lesion, or a diffusely infiltrative (scirrhous) lesion that narrows the lumen. Histologically it is graded by degree of keratinisation and intercellular bridge formation (well, moderate, poorly differentiated). Molecular alterations commonly involve TP53, NOTCH1, CCND1 amplification, PIK3CA, and EGFR. [1]

Adenocarcinoma and the Barrett's Metaplasia-Dysplasia-Carcinoma Sequence

ADC arises through the canonical metaplasia → dysplasia → carcinoma sequence driven by chronic acid and bile reflux. The molecular hallmarks include TP53 mutation (early), CDKN2A loss, SMAD4/DPC4, ERBB2 (HER2) amplification (20-30%, targetable), and VEGFA amplification. The morphological precursor is Barrett's oesophagus, discussed in detail below. Adenocarcinomas most often produce a nodular, ulcerated mass at the GOJ. [1]

Barrett's Oesophagus and Chemoprevention

Barrett's oesophagus is the replacement of the normal stratified squamous epithelium of the distal oesophagus by metaplastic columnar epithelium with goblet cells (intestinal metaplasia) — a consequence of chronic GORD. The British Society of Gastroenterology definition requires intestinal metaplasia for diagnosis, while the American College of Gastroenterology accepts any columnar metaplasia of 1 cm or more. [1]

• Cancer risk: approximately 0.5% per year (some recent Scandinavian data suggest lower, ~0.1–0.3%) in non-dysplastic Barrett's; rises to 5–10% per year with high-grade dysplasia.
• Risk factors for progression: male sex, white race, age over 50, BMI over 30 (central adiposity), smoking, segment length over 3 cm (long-segment Barrett's), family history, and the presence of dysplasia. [1]

The Metaplasia-Dysplasia-Carcinoma Sequence

The stepwise pathway: normal squamous → simple columnar metaplasia → intestinal metaplasia (Barrett's) → low-grade dysplasia → high-grade dysplasia → intramucosal carcinoma → invasive adenocarcinoma. This mirrors the colorectal adenoma-carcinoma sequence and provides the window for endoscopic surveillance and ablative therapy to interrupt carcinogenesis. [1]

Surveillance Protocol

Radiofrequency Ablation (RFA)

• Halo system — a bipolar electrode balloon/focal catheter delivering controlled thermal energy to the Barrett's mucosa.
• Produces ablation of the metaplastic epithelium with subsequent squamous re-epithelialisation.
• Reduces progression to cancer by around 90% in confirmed high-grade dysplasia (AIM-II and other studies).
• Complications: stricture (5–10%), bleeding (1%), perforation (under 1%), pain.
• Stepwise radial ablation is preferred to avoid circumferential stricture. [1]

Endoscopic Resection (EMR / ESD)

Endoscopic mucosal resection (EMR) is both diagnostic and therapeutic for visible (nodular) lesions — it provides T-staging histology and can completely resect T1a lesions. Endoscopic submucosal dissection (ESD) allows en-bloc resection of larger early lesions. Any visible lesion within Barrett's must be resected first (rather than ablated) to obtain histology and exclude submucosal invasion that would mandate surgery. [1]

Chemoprevention

• High-dose PPI therapy — suppresses acid, may reduce metaplasia progression; recommended for all Barrett's patients.
• Aspirin — the AspECT trial showed aspirin + high-dose PPI reduced oesophageal cancer mortality over long-term follow-up; not yet universally adopted.
• Statins and metformin — observational signal of reduced progression; not standard.
• Lifestyle — weight loss (target BMI under 25), smoking cessation, alcohol moderation, dietary modification (Mediterranean diet, avoid late meals). [1]

Clinical Presentation

Oesophageal cancer is characteristically silent until locally advanced because the oesophagus has a wide, distensible lumen and a sparse pain fibre supply. [1]

• Progressive dysphagia — the hallmark: solids first (mechanical obstruction, luminal diameter reduced by approximately 50%), then soft foods, then liquids. By the time liquids cannot be swallowed, the tumour is usually advanced. "The oesophagus has to be half-obstructed before the patient notices."
• Weight loss — mean around 10 kg at presentation; a poor prognostic sign and a marker of malnutrition that must be addressed before treatment.
• Odynophagia (painful swallowing) — suggests deep invasion or an ulcerating lesion.
• Regurgitation of undigested food (not acidic — distinguishes from GORD) — suggests a functionally obstructed lumen.
• Hoarse voice — recurrent laryngeal nerve involvement (usually left); indicates advanced (T4b) disease.
• Horner's syndrome (ptosis, miosis, anhidrosis) — invasion of the sympathetic chain / stellate ganglion; advanced.
• Chronic anaemia — occult upper GI bleeding from an ulcerating tumour, especially ADC at the GOJ.
• Aspiration pneumonia — from a tracheo-oesophageal fistula (a catastrophic complication, usually palliated with a covered stent) or nocturnal regurgitation.
• Cervical lymphadenopathy — Virchow's node (Troisier's sign, supraclavicular) — a classical sign of metastatic disease.
• Hepatomegaly, ascites, bone pain — distant metastases at presentation (liver most common, then lung, then bone). [1]

Differential Diagnosis of Dysphagia

A high-yield examination framework separates mechanical obstruction from neuromuscular/motility causes: [1]

Key discriminator: In mechanical obstruction, solids are difficult first; in motility disorders, liquids and solids are equally difficult from the outset and symptoms may improve with postural manoeuvres or repeated swallowing. [1]

Staging Workup

Accurate staging determines operability, the choice of neoadjuvant therapy, and prognosis. The standard staging battery for a newly diagnosed oesophageal cancer: [1]

Why each test matters: EUS is uniquely able to assess the depth of wall invasion (T) and is the single most accurate test for early T-staging and for selecting patients for endoscopic therapy (T1a) versus surgery (T1b and beyond). PET-CT upstages ~15% of patients by detecting occult M1 disease, sparing futile surgery. Laparoscopy specifically catches peritoneal metastases that are below the resolution of CT — most relevant for ADC at the GOJ, which behaves biologically like gastric cancer. [1]

TNM 8th Edition Staging

The AJCC/UICC 8th edition (2017, in clinical use since 2018) introduced major changes for oesophageal cancer: separate stage groupings for SCC and ADC (because the same TNM combination carries a different prognosis by histology), a new prognostic grade and tumour location modifier, and a refined N category based on the absolute number of positive nodes. [1]

T Stage (Primary Tumour) — applies to both SCC and ADC

N Stage — based on absolute number of involved regional nodes

The move to a numeric N category reflects the strong prognostic effect of nodal burden and incentivises an adequate lymphadenectomy (a minimum of 15 nodes is recommended for accurate staging). [1]

M Stage

Stage Groups and Prognosis (Simplified)

The 8th edition produces separate groupings for SCC and ADC. The following is a practical, simplified composite: [1]

Additional 8th-edition prognostic modifiers: histological grade (G1–G3), tumour location (upper/mid/lower), and (for SCC) these can shift the stage group. These reflect the recognition that biology — not just anatomy — drives prognosis. [1]

Siewert Classification (Gastro-Oesophageal Junction Tumours)

Adenocarcinomas at the gastro-oesophageal junction straddle the boundary between "oesophageal" and "gastric" cancer and behave differently. The Siewert classification (1998) stratifies them by the epicentre of the tumour relative to the anatomical GOJ: [1]

Examiner point: The Siewert classification dictates both the neoadjuvant strategy (CROSS for I; FLOT for II/III) and the surgical approach (oesophagectomy vs gastrectomy). It should be stated for any GOJ adenocarcinoma in a viva. [1]

Pre-operative Fitness Assessment

Oesophagectomy is one of the most physiologically stressful elective operations, with a mortality of 2–5% and a major morbidity of 30–50% (chiefly respiratory and anastomotic). Pre-operative assessment stratifies risk and optimises the patient. [1]

Cardiopulmonary Exercise Testing (CPET)

CPET provides an objective, integrated measure of cardiorespiratory reserve. [1]

• Anaerobic threshold (AT): over 11 mL O2/kg/min = low risk; 8–11 = intermediate; under 8 = high risk.
• VO2 peak: over 15 mL/kg/min acceptable; under 15 warrants caution.
• VE/VCO2 slope: under 42 acceptable; over 42 indicates poor ventilatory efficiency. [1]

Risk stratification:

• Low risk — AT over 11, normal ECG, good functional capacity (METs over 4) → proceed with surgery.
• Intermediate risk — AT 8–11 → optimise comorbidities, smoking cessation, MDT discussion.
• High risk — AT under 8 → consider definitive chemoradiotherapy (dCRT) or palliation. [1]

Nutritional Optimisation

Malnutrition (present in over half of patients) doubles post-operative morbidity. [1]

• Enteral feeding via nasojejunal or feeding jejunostomy for dysphagia or weight loss over 10%.
• Parenteral nutrition reserved for enteral failure or severe malnutrition.
• Target: serum albumin over 30 g/L, weight stabilisation before surgery.
• Pre-operative immunonutrition (arginine, omega-3 fatty acids, nucleotides) for 5–7 days reduces post-operative infective complications. [1]

Treatment — Multimodal Therapy for Resectable Cancer

For resectable (stage I–III, M0) oesophageal cancer, surgery alone gives poor results (5-year survival 15–25% for stage II/III). Two landmark neoadjuvant strategies have transformed outcomes: chemoradiotherapy (CROSS) and perioperative chemotherapy (FLOT). [1]

[1]

CROSS Protocol — Detailed Neoadjuvant Chemoradiotherapy

The CROSS regimen (Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study, van Hagen et al., NEJM 2012) is the global standard for locally advanced SCC and oesophageal ADC (Siewert I). [1]

Chemotherapy (weekly for 5 weeks):

• Carboplatin — AUC 2 mg/mL/min IV on day 1 of each weekly cycle.
• Paclitaxel — 50 mg/m² IV on day 1 of each weekly cycle. [1]

Radiotherapy:

• Total dose 41.4 Gy in 23 fractions (1.8 Gy per fraction, Monday–Friday, over 4.5 weeks).
• Target volume: primary tumour with 4 cm cranial and caudal margins and the regional lymph nodes (based on tumour location). [1]

Surgery:

• Performed 4–6 weeks after completion of CRT to allow recovery and the radiation inflammatory response to settle.
• R0 (microscopically clear margin) resection rate: 92% (vs 69% surgery alone). [1]

Key CROSS outcomes (NEJM 2012, long-term Lancet Oncol 2015):

• Median overall survival: 49.4 months (CRT+S) vs 24.0 months (S alone).
• 5-year survival: 47% vs 34%.
• Pathological complete response (pCR): 29% (vs 0% with surgery alone) — 49% of SCC and 23% of ADC.
• Benefit demonstrated in both SCC and adenocarcinoma subtypes, though more pronounced in SCC.
• Treatment was well tolerated, with 96% completing CRT; 21% grade 3–4 haematological toxicity. [1]

FLOT Protocol — Detailed Perioperative Chemotherapy

The FLOT regimen has superseded the older MAGIC-era ECF (epirubicin/cisplatin/5-FU) and is now the preferred perioperative chemotherapy for adenocarcinoma, especially Siewert II/III GOJ tumours. [1]

FLOT (given every 2 weeks for 4 cycles pre-op + 4 cycles post-op):

• F — 5-Fluorouracil 2600 mg/m² continuous IV infusion over 24 hours, day 1.
• L — Leucovorin (folinic acid) 200 mg/m² IV, day 1.
• O — Oxaliplatin 85 mg/m² IV, day 1.
• T — Docetaxel 75 mg/m² IV, day 1. [1]

FLOT4-AIO trial (Al-Batran et al., Lancet 2019):

• 5-year overall survival: 45% (FLOT) vs 36% (ECF/ECX) — a 9% absolute improvement.
• Improved progression-free survival and locoregional control.
• More grade 3–4 neutropenia and infection than ECF but manageable. [1]

CROSS vs FLOT — when to use which?

• CROSS (chemoradiotherapy) — preferred for SCC anywhere, and for oesophageal ADC (Siewert I).
• FLOT (perioperative chemo) — preferred for GOJ/gastric adenocarcinoma (Siewert II/III).
• An ongoing ESOPEC trial compares perioperative FLOT directly against CROSS for ADC; emerging data suggest comparable or superior outcomes with CROSS in some ADC subgroups. [1]

Neoadjuvant Therapy Response Assessment

Assessing response is important for prognostication and, in trials, for guiding adjuvant or salvage strategies. [1]

• Clinical/radiological response: repeat CT and PET-CT (fall in SUV-max), repeat EUS (reduction in wall thickness), occasionally repeat OGD with biopsies.
• Pathological response (gold standard, on the resected specimen):
  • Mandard Tumour Regression Grade (TRG 1–5): TRG 1 = complete response (fibrosis, no residual tumour cells); TRG 2 = rare residual cells; ... TRG 5 = no regression. TRG 1–2 define a major response.
  • pCR (pathological complete response): no viable tumour in the resected oesophagus and nodes — seen in ~29% of CROSS (49% SCC, 23% ADC).
• Prognostic value: pCR and TRG 1–2 carry a markedly better survival (5-year survival approaching 60–70%) than non-responders. [1]

Surgical Approaches — Detailed

The aim of surgery is an R0 resection with an adequate proximal and distal margin, an adequate lymphadenectomy, and reconstruction (almost always with a gastric conduit anastomosed in the chest or neck). [1]

Ivor Lewis Oesophagectomy (2-Stage)

The workhorse operation for mid- and lower-third tumours. Performed in two stages: [1]

1. Stage 1 — Laparotomy (or laparoscopy):
   • Gastric mobilisation, carefully preserving the right gastroepiploic and right gastric arteries (these will supply the gastric conduit).
   • Pyloroplasty or pyloromyotomy (occasionally pyloric botulinum toxin) — a drainage procedure to prevent delayed gastric emptying of the denervated conduit.
   • Feeding jejunostomy for post-operative nutrition.
   • D2 lymphadenectomy for lower-third/GOJ tumours as appropriate.
   • Formation of the gastric tube (along the greater curvature) to be pulled up into the chest.
2. Stage 2 — Right thoracotomy (or thoracoscopy):
   • Mobilise the intrathoracic oesophagus.
   • Resect the tumour with adequate proximal margin (typically 5 cm or more for SCC).
   • Intrathoracic anastomosis (stapled circular or hand-sewn) at the apex of the right pleural cavity. [1]

Pros: excellent exposure of mid/lower thoracic oesophagus; one anastomosis; lower leak rate than cervical. Cons: an intrathoracic anastomotic leak is catastrophic (mediastinitis, 10–30% mortality). [1]

McKeown Oesophagectomy (3-Stage)

1. Right thoracotomy/thoracoscopy — oesophageal mobilisation.
2. Laparotomy/laparoscopy — gastric mobilisation and conduit formation.
3. Cervical incision — cervical anastomosis. [1]

Pros: the cervical anastomosis leaks more often (10–15%) but is far less lethal (manageable with opening the wound and drainage, mortality under 5%); suitable for upper thoracic and cervical tumours. Cons: higher recurrent laryngeal nerve injury rate; higher anastomotic stricture rate; reflux. [1]

Transhiatal Oesophagectomy (Orringer)

• Laparotomy for gastric mobilisation and blind/transhiatal mediastinal mobilisation of the oesophagus, with a cervical anastomosis.
• Avoids thoracotomy — useful for patients with poor respiratory reserve and for cervical or upper-third tumours.
• Pros: no thoracotomy (fewer respiratory complications), cervical anastomosis. Cons: limited mediastinal lymphadenectomy (worse nodal staging), risk of major bleeding from aortic branches and tracheobronchial injury during blind blunt dissection, higher RLN injury. [1]

Minimally Invasive and Robotic Oesophagectomy

• Hybrid (laparoscopic + thoracotomy or open + thoracoscopic) or totally minimally invasive oesophagectomy (MIO, VATS + laparoscopy).
• Robotic-assisted oesophagectomy offers 3D vision and wristed instruments in the confines of the thoracic inlet.
• MIRO trial and meta-analyses: reduced respiratory complications, less blood loss, shorter hospital stay, similar oncological outcomes (R0 rates, node yield, survival) to open surgery.
• Disadvantage: steep learning curve, longer operative time, cost, and reduced tactile feedback. [1]

Lymphadenectomy — 2-Field vs 3-Field

The extent of lymphadenectomy is one of the most debated topics in oesophageal surgery, and a frequent viva question. [1]

• 2-field lymphadenectomy: removal of the abdominal (coeliac, left gastric, common hepatic, splenic) and mediastinal (paratracheal, subcarinal, para-oesophageal) nodal basins. The standard for most Western centres.
• 3-field lymphadenectomy: adds the cervical (bilateral cervical, supraclavicular, recurrent laryngeal nerve chain) nodes. Pioneered in Japan, where the high incidence of SCC and its propensity for upper/cervical lymphatic spread justify the more extensive dissection. [1]

Evidence and controversy: Japanese data show 3-field dissection improves survival in selected SCC patients with upper-field nodal disease; Western randomised data is lacking and the operation carries a higher RLN injury and respiratory morbidity. The compromise is the 2-field + cervical node sampling approach. A minimum of 15 lymph nodes should be retrieved for adequate staging. [1]

Gastric Conduit and Reconstruction

• The stomach is the preferred conduit (single anastomosis, robust blood supply from the right gastroepiploic artery, sufficient length to reach the neck).
• Alternative conduits: colon (interposition, with its own mesenteric blood supply) or jejunum (free graft or pedicled, Merendino for short Siewert I segments).
• Position: usually posterior mediastinum (original oesophageal bed), retrosternal, or subcutaneous (rare, for re-do or salvage). [1]

Post-operative Complications

Oesophagectomy has a major morbidity of 30–50%. High-yield complications: [1]

• Respiratory (most common, 20–30%) — atelectasis, pneumonia, pleural effusion, ARDS; reduced by minimally invasive surgery, early mobilisation, EPAP.
• Anastomotic leak (5–15%) — see below.
• Anastomotic stricture (10–30%) — late, dilated endoscopically.
• Recurrent laryngeal nerve palsy — hoarseness, aspiration, especially after cervical anastomosis/3-field.
• Delayed gastric emptying / conduit dysfunction — nausea, regurgitation; mitigated by pyloroplasty.
• Chylothorax (1–3%) — injury to the thoracic duct; managed by NPO + medium-chain triglyceride diet or surgical ligation if persistent.
• Atrial fibrillation — common (15–20%), often the first sign of an anastomotic leak or mediastinal complication.
• Conduit necrosis — rare (1–2%) but catastrophic; requires re-operation and conduit removal. [1]

Anastomotic Leak Management

An anastomotic leak remains the most feared complication; its severity depends on the site (intrathoracic worse than cervical) and containment. [1]

Clinical presentation (typically day 5–10):

• Fever, tachycardia, sepsis, tachypnoea.
• Pleural effusion (classically right-sided for an intrathoracic anastomosis).
• Mediastinitis, surgical emphysema, subcutaneous emphysema.
• New atrial fibrillation — a sentinel sign of mediastinal irritation that should prompt active exclusion of a leak. [1]

Diagnosis:

• Water-soluble contrast swallow (Gastrografin — note the small aspiration risk; some use dilute barium) — extravasation at the anastomosis.
• CT chest with oral contrast — defines abscess collection, mediastinal extent, pleural involvement, and guides drainage.
• Endoscopy — direct visualisation and a route for therapy; safe if performed gently. [1]

Management — graded by severity:

• Nil by mouth + broad-spectrum IV antibiotics (piperacillin-tazobactam + metronidazole; add antifungal in prolonged leaks) + IV PPI.
• Chest drain / radiological drainage of pleural effusion, empyema or mediastinal collection.
• Nutritional support — feeding jejunostomy (placed prophylactically at primary surgery precisely for this event) or nasojejunal; rarely TPN.
• Endoscopic therapy for contained leaks — fully covered self-expanding metal stent (FCSEMS), endoscopic vacuum-assisted closure (E-VAC, sponge therapy), or endoscopic clipping of small defects.
• Surgical re-exploration — for uncontrolled sepsis, complete dehiscence, conduit necrosis, or failed conservative/endoscopic management; options include repair, drainage, takedown with cervical oesophagostomy, or conduit resection.
• Mortality: 10–30% for intrathoracic leaks (far higher than cervical leaks, which are typically managed by wound opening and drainage with under 5% mortality). [1]

Palliative Management (Unresectable/Metastatic)

Around half of patients present with unresectable or metastatic disease, where the goals shift to dysphagia relief, nutritional support, and quality of life. [1]

Endoscopic Palliation

Self-expanding metal stent (SEMS):

• Covered, partially covered, or fully covered metal mesh tube deployed under endoscopic and fluoroscopic guidance across the tumour.
• Immediate relief of dysphagia in 90–95%.
• Indications: malignant dysphagia, tracheo-oesophageal fistula (covered stent), poor-prognosis patients needing rapid palliation.
• Complications: migration (5–10%), tumour in-growth (uncovered stents, 15–20%), reflux (lower-third stents, as the LOS is bypassed — consider an anti-reflux stent), perforation (1–2%), bleeding, chest pain, overgrowth.
• Lifespan: typically 3–6 months (often need replacement). [1]

Laser recanalisation (Nd:YAG):

• Thermal ablation of exophytic intraluminal tumour to recanalise the lumen.
• Multiple sessions required; risk of perforation; useful for bulky, exophytic tumours. [1]

Photodynamic therapy (PDT):

• A systemic photosensitiser (porfimer sodium) is given; the tumour is then illuminated by laser light at the activating wavelength, generating cytotoxic reactive oxygen species and selective tumour necrosis.
• Advantage: deeper necrosis than thermal modalities; disadvantage: cutaneous photosensitivity for 4–6 weeks (patient must avoid sunlight). [1]

Brachytherapy (intraluminal radiotherapy):

• A high-dose-rate iridium-192 source placed via an intraluminal catheter delivers localised radiation.
• Comparable durable dysphagia relief to stenting with better long-term quality of life (SBR study); useful for tumours not suitable for stenting. [1]

Argon plasma coagulation (APC) and dilation — adjuncts for minor recanalisation. [1]

Systemic Palliative Therapy

• Chemotherapy — for fit patients (ECOG PS 0–1): FLOT, FOLFOX, or ECF/ECX; improves median survival from ~6 months (best supportive care) to ~10–12 months.
• Targeted therapy:
  • Trastuzumab (anti-HER2 monoclonal) for HER2-positive adenocarcinoma (ToGA trial) — HER2 testing is mandatory for ADC.
  • Ramucirumab (anti-VEGFR2) second-line (REGARD, RAINBOW) — modest survival benefit, alone or with paclitaxel.
• Immunotherapy (checkpoint inhibitors):
  • Pembrolizumab (anti-PD-1) — first-line for MSI-high or TMB-high tumours (KEYNOTE-177/158/180/181), and for PD-L1 CPS over 10 (KEYNOTE-590).
  • Nivolumab ± ipilimumab — CheckMate 577 (adjuvant nivolumab for non-pCR patients after neoadjuvant therapy improves disease-free survival) and CheckMate 648 (first-line nivolumab + chemo or nivo + ipi for advanced SCC).
• Best supportive care — analgesia (WHO ladder, including coeliac plexus block for back pain), nutritional support (PEG/PEJ in selected cases — though risk of tumour seeding along the track exists), and palliative care input. [1]

Tracheo-Oesophageal Fistula (Special Situation)

A tracheo-oesophageal fistula (TEF) in oesophageal cancer is a catastrophic complication causing cough on drinking, recurrent aspiration pneumonia, and rapid decline. Management is palliative: a fully covered dual (oesophageal + tracheal) SEMS to seal the fistula, antibiotics for aspiration, and nutritional support. Surgery is rarely appropriate. [1]

Follow-up and Surveillance

Post-treatment surveillance:

• Clinical review every 3 months for 2 years, then 6-monthly to 5 years (most recurrences occur within 2 years).
• CT chest/abdomen/pelvis at 6, 12, 18, 24 months, then as clinically indicated.
• OGD if symptoms recur (dysphagia, weight loss) — to detect local recurrence or a second primary.
• Nutritional assessment and dietary support (small frequent meals, proton pump inhibitor for reflux, anti-diarrhoeals for dumping).
• Quality-of-life monitoring (EORTC QLQ-OES18/OES25).
• CheckMate 577 has established adjuvant nivolumab for patients without a pCR after neoadjuvant therapy — increasingly incorporated into surveillance pathways. [1]

Barrett's surveillance (premalignant): as detailed above — OGD every 3–5 years (no dysplasia), 6–12 months (LGD with RFA), endoscopic resection + RFA (HGD). [1]

Prognosis

Prognosis is driven by stage at presentation, histological response to neoadjuvant therapy, R0 resection status, and performance status. [1]

Prognostic summary by stage (approximate 5-year survival):

• Stage 0 (Tis): over 80%
• Stage I: 60–80%
• Stage II: 30–50%
• Stage III (after CROSS): 25–35%
• Stage IV (M1): under 5% [1]

Favourable prognostic factors: early stage, pCR / TRG 1–2 after neoadjuvant therapy, R0 resection, fewer than 3 positive nodes, good performance status, ADC over SCC for matched stage (in some series), and complete (R0) resection with adequate nodal yield. [1]

Exam Tips and High-Yield Points

• Two histologies, two stories: SCC (upper/mid, smoking+alcohol, global South) vs ADC (lower/GOJ, Barrett's+obesity, West). Always specify which you are discussing.
• Barrett's = intestinal metaplasia with goblet cells (UK definition); the metaplasia-dysplasia-carcinoma sequence is exam gold.
• CROSS for oesophageal tumours (SCC + Siewert I); FLOT for GOJ/gastric (Siewert II/III). State doses: carboplatin AUC 2 + paclitaxel 50 mg/m² weekly × 5 + 41.4 Gy/23 fractions.
• pCR is prognostic gold; CheckMate 577 offers adjuvant nivolumab to non-responders.
• Ivor Lewis = laparotomy + right thoracotomy + intrathoracic anastomosis. Cervical leaks are common but safe; intrathoracic leaks are rare but lethal.
• No serosa on the thoracic oesophagus — explains early transmural spread.
• New atrial fibrillation post-oesophagectomy = rule out anastomotic leak.
• Siewert I = oesophagus, II = junctional, III = gastric — drives treatment.
• Tylosis (Howel-Evans) = nearly 100% lifetime SCC risk.
• Helicobacter pylori is protective for ADC (counter-intuitive — high yield).
• Minimum 15 lymph nodes for adequate staging. [1]

Exam application bank (NEET-PG / INICET)

One-line answer

Oesophageal cancer is the 8th most common cancer worldwide. Squamous cell carcinoma predominates globally (Asia, Africa); adenocarcinoma predominates in Western countries (Barrett's oesophagus from GORD). Presentation: progressive dysphagia (solids then liquids), weight loss. Staging: endoscopy + biopsy, EUS (T/N staging), CT/PET-CT (M staging), laparoscopy for GOJ tumours. Multimodal treatment: neoadjuvant ChemoRT (CROSS: carboplatin + paclitaxel + 41.4 Gy) then surgery (Ivor Lewis oesophagectomy).

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Oesophageal Cancer.

[1]

References

1. [1]van Hagen P, Hulshof MCC, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012.PMID 22646630